Sign inJoin waitlistJoin the waitlist

Bhavana Konda

Section Chief, Neuroendocrine Tumors · Ohio State University Hospital

Credentials: · · · · · ·

History

Neuroendocrine Tumors Section · Ohio State University Hospital
Present
Ohio State University Hospital
Present

University of Miami
2010–2013
Internal Medicine
HCA Florida JFK Hospital/University of Miami Miller School of Medicine GME Consortium
2007–2010
Doctor of Medicine
2003–2007

Research

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil…
Journal of Clinical Oncology · 1998 · 447 citations
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label,…
The Lancet Oncology · 2022 · 384 citations
Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter…
Thyroid · 2022 · 134 citations

MS
Manisha Shah
30 papers
Vineeth Sukrithan
18 papers
Jordan Cloyd
10 papers · 5 as a fellow
Dwight Owen
9 papers · 3 as a fellow
Mary Dillhoff
9 papers
Timothy Pawlik
9 papers
Jennifer Sipos
6 papers
LK
Lawrence Kirschner
6 papers
William Carson
6 papers
Carl Schmidt
5 papers
Fadi Nabhan
5 papers
Robert Wesolowski
5 papers

Clinical trials

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2026–2029
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2020–2026
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Principal investigator · Completed · Phase 2
Bhavana Konda
2012–2022
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2006–2022